COMMUNIQUÉS West-GlobeNewswire

FOXO Technologies Inc. Subsidiary, Big South Fork Medical Center, Expands Clinical Capabilities
20/01/2026
WEST PALM BEACH, FL, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “Company”) today announced that its critical access-designated acute care hospital, Scott County Community [...]
Machina Medical Receives FDA 510(k) Clearance for MFUSE External Bleeding Control Device
20/01/2026
ROSWELL, Ga., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Machina Medical, Corp. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MFUSE, a sterile, single-use medical device [...]
Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
20/01/2026
Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect Biosystems Aspect will lead development, manufacturing and commercialisation, and Novo Nordisk will have defined [...]
Radix Health Rebrands as Pivotal Health
20/01/2026
Following rapid adoption of its Independent Dispute Resolution technology, Pivotal Health broadens its mission to help providers achieve fair reimbursement through technology NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- [...]
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
20/01/2026
MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies, today announced continued [...]
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
20/01/2026
If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026 QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va [...]
BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions
20/01/2026
SAN JOSE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BrightInsight , a leader in digital health solutions, today announced a new investment round of $13 million from existing and new investors including Eclipse, General [...]
InStride Health and The Wharton School Showcase Successful AI Scribe Adoption for Improved Clinician Efficiency and Experience
20/01/2026
Case study highlights how collaboration from clinical and technical teams drive effective, responsible, and scalable AI adoption in behavioral health BOSTON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InStride [...]
FibroBiologics to Present at the DealFlow Discovery Conference
20/01/2026
HOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
BrightInsight Strengthens Executive Leadership Team with Three Key Hires to Accelerate Global Growth and Innovation
20/01/2026
SAN JOSE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BrightInsight, Inc ., the leading global platform for biopharma digital health solutions, today announced the appointment of three industry veterans to its Executive [...]
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
20/01/2026
A World-First, Fully Synthetic Recombinant Version of PRP MELBOURNE, , Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on [...]
Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study
20/01/2026
Innovative Trial Design to Directly Measure Microvascular Functional Effects of Inhaled Therapy at the Capillary level of Pulmonary Hypertension Patients with Interstitial Lung Disease (PH-ILD) DURHAM, NC and LONDON, [...]
SPARK NS and Haukeland University Hospital Announce Clinical Trial of D-Serine for Modifying Parkinson’s Disease Progression
20/01/2026
Previous research indicates that D-Serine is safe, tolerable, and holds promise as a potential neuroprotective treatment for Parkinson’s MENLO PARK, Calif. and BERGEN, Norway, Jan. 20, 2026 (GLOBE NEWSWIRE) -- SPARK NS [...]
Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure
20/01/2026
Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free balance sheet and positive Net [...]
New Imprivata Survey Finds 85% of Healthcare IT Leaders Think Passwordless Authentication is Vital, but Adoption Lags Significantly
20/01/2026
Just 7% of organizations have fully adopted passwordless authentication, citing technical integration challenges and clinical training concerns WALTHAM, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Imprivata , a leading [...]
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
20/01/2026
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence [...]
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/01/2026
MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the [...]
Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis
20/01/2026
SANDWICH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food [...]
smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris
20/01/2026
Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from [...]

Pages